VivoSim showcases advanced liver toxicology prediction model at healthcare conference

From GlobeNewswire: 2025-05-07 08:05:00

VivoSim Labs, Inc. announced the success of its NAMkind™ platform for liver toxicology prediction, showcasing 87.5% predictive power against a set of liver compounds at the Digestive Disease Week Conference. The platform demonstrated 100% specificity, correctly identifying liver-toxic drugs. VivoSim’s liver model is made from human donor cells and aims to reduce drug development costs by 50% by improving clinical trial success rates. The FDA’s move to phase out animal testing will boost VivoSim’s market adoption, offering transformative solutions for drug development challenges such as liver and intestinal toxicities. VivoSim is poised to provide superior outcomes for pharmaceutical customers and patients by leveraging AI and human organ model-based lab testing to deliver safer treatments more efficiently.



Read more at GlobeNewswire: VivoSim Presents Best-in-Class Liver Toxicology Prediction